<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2015-05914-666-12182</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Development of a molecular surveillance phylogeographic tool to track HIV transmission networks in Bangladesh</narrative>
   <narrative xml:lang="SV">Utvecklande av en molekyl&#xE4;r fylogeografisk metod f&#xF6;r att f&#xF6;lja HIV smittokedjor i Bangla-Desh</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Aims The aim is to develop a cost-effective molecular surveillance phylogeographic tool and use it to understand the intra- and inter-country movement of HIV strains in Bangladesh and inform on strategies how to combat the HIV epidemic. Three substudies will be done: i) To develop a near-full-length-genome protocol adopted for HIV strains in Bangladesh; ii) To develop a phylogeographic model for cluster analysis by integrating virus sequences with epidemiological, demographical and behavioural data, to understand the dynamics of transmission; iii) To validate and implement the model in Bangladesh to inform and support preventive measures. Project description and mode of cooperation The KI researchers will develop two cost-effective and simplified tools: i) a full-genome sequencing assay (NFLG) based on modern next generation sequencing; ii) an high-resolution Bayesian phylogeographic model. By combining the methods, we will creat a powerful tool to understand the spatial and temporal movements of HIV. A larg number of plasma samples (n= 400) will be analysed from clients attending an HIV Testing and Counselling (HTC) services at Dhaka Hospital. The virus full-genome sequence data will be analysed together with epidemiological, demographical, and behavioural data.  The design of the study is done together by the partners from KI and Bangladesh. The initial development of the assay and the phylogeopgraphic model will be done at KI. Thereafter the methods are transferred to</narrative>
   <narrative xml:lang="SV">Vi avser att utveckla en ny metod f&#xF6;r att b&#xE4;ttre kunna beskriva och f&#xF6;lja befintliga och nya n&#xE4;tverk av hiv-1 infektioner i Bangladesh. Genom att analysera en begr&#xE4;nsad del av hivs arvsmassa har vi tidigare konstaterat att hiv-1 har introducerats ett flertal g&#xE5;nger i Bangladesh fr&#xE5;n n&#xE4;rliggande l&#xE4;nder och genom g&#xE4;starbetare som &#xE5;terv&#xE4;nder fr&#xE5;n Mellersta &#xF6;stern. Vi har nu utvecklat en kostnadseffektiv sekvenseringsmetod som kan kartl&#xE4;gga n&#xE4;stan hela HIV-1 genomet (kallad NFLG). Dessutom arbetar vi med att vidareutveckla fylogeografiska metoder i vilka vi kombinerar virusets gensekvenser med epidemiologiska, kliniska och beteende-data f&#xF6;r att f&#xE5; information om hiv-1 stammarnas r&#xF6;relse i tid och rum i ett land. Genom att kombinera dessa metoder kommer vi att f&#xE5; ett kraftfullt verktyg f&#xF6;r att f&#xF6;lja hiv-1 epidemin i Bangladesh, f&#xF6;lja spridningen av befintliga stammar och identifiera uppkomsten av nya stammar. Denna kunskap kommer att kunna anv&#xE4;ndas som st&#xF6;d f&#xF6;r f&#xF6;rst&#xE5;elsen f&#xF6;r spridningen av hiv-1 och designen av preventiva  &#xE5;tg&#xE4;rder f&#xF6;r att motverka detta. Metodutvecklingen sker initialt vid Karolinska Institutet och forskare fr&#xE5;n Bangladesh l&#xE4;r sig metoden. D&#xE4;refter &#xF6;verf&#xF6;rs kunskapen till Bangladesh d&#xE4;r ett st&#xF6;rre antal prover fr&#xE5;n hiv-1 smittade personer f&#xF6;r den senaste 10 &#xE5;rs perioden kommer att analyseras. Forskarna fr&#xE5;n KI och Bangladesh kommer under slutfasen tillsammans analysera data, beskriva hiv-1 epidemin i Bangladesh och ge information till myndigheter vilken kan anv&#xE4;ndas f&#xF6;r nationella strategier f&#xF6;r att motverka hiv-1 epidemin</narrative>
  </description>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">University, college or other teaching institution, research institute or think-tank</narrative>
  </participating-org>
  <activity-status code="3"></activity-status>
  <activity-date iso-date="2016-01-01" type="1"></activity-date>
  <activity-date iso-date="2019-12-31" type="3"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="BD" percentage="100">
   <narrative xml:lang="EN">Bangladesh</narrative>
  </recipient-country>
  <sector code="121" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Health, General</narrative>
  </sector>
  <sector code="12182" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Medical research</narrative>
  </sector>
  <tag code="3.B" vocabulary="3">
   <narrative xml:lang="SV">3.b - St&#xF6;dja forskning om och utveckling av vaccin och l&#xE4;kemedel mot de smittsamma och icke-smittsamma sjukdomar som i f&#xF6;rsta hand drabbar utvecklingsl&#xE4;nder. S&#xF6;rja f&#xF6;r tillg&#xE5;ng till ekonomiskt &#xF6;verkomliga grundl&#xE4;ggande l&#xE4;kemedel och vaccin, i enlighet med Doha-deklarationen om TRIPS-avtalet och folkh&#xE4;lsa, i vilken det bekr&#xE4;ftas att utvecklingsl&#xE4;nderna har r&#xE4;tt att fullt ut utnyttja den flexibilitet som avtalet om handelsrelaterade aspekter av immaterialr&#xE4;tter erbjuder f&#xF6;r att skydda folkh&#xE4;lsan och, framf&#xF6;r</narrative>
   <narrative xml:lang="EN">3.b - Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public healt</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">44410.6819377082</value>
  </budget>
  <budget>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">44460.0444600445</value>
  </budget>
  <budget>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">43726.4107520943</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-11-27"></transaction-date>
   <value currency="USD" value-date="2015-11-27">135242.5468306977</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-01-28"></transaction-date>
   <value currency="USD" value-date="2016-01-28">44410.6819377082</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-01-28"></transaction-date>
   <value currency="USD" value-date="2017-01-28">44460.0444600445</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-01-28"></transaction-date>
   <value currency="USD" value-date="2018-01-28">43726.4107520943</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
